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Abstract CYP27B1 encodes mitochondrial 1a-hydroxy-
lase,whichconverts25-hydroxyvitaminDtoitsactive1,25-
dihydroxylated metabolite. We tested the hypothesis that
common variants in the CYP27B1 promoter are associated
with fracture risk. The study was designed as a population-
based genetic association study, which involved 153 men
and 596 women aged 65–101 years, who had been followed
for2.2 years(range0.1–5.5)between1999and2006.During
the follow-up period, the incidence of fragility fractures was
ascertained. Bone ultrasound attenuation (BUA) was
measured in all individuals, as were serum 25-hydroxyvita-
min D and PTH concentrations; 86% subjects had vitamin
D insufﬁciency. Genotypes were determined for the
–1260C[A (rs10877012) and ?2838T[C (rs4646536)
CYP27B1polymorphisms.Areportergeneassaywasusedto
assess functional expression of the –1260C[A CYP27B1
variants. The association between genotypes and fracture
risk was analyzed by Cox’s proportional hazards model. We
found that genotypic distribution of CYP27B1 –1260 and
CYP27B1 ?2838 polymorphisms was consistent with the
Hardy-Weinberg equilibrium law. The two polymorphisms
were in high linkage disequilibrium, with D0 = 0.96 and
r
2 = 0.94. Each C allele of the CYP27B1 –1260 polymor-
phism was associated with increased risk of fracture (hazard
ratio = 1.34, 95% CI 1.03–1.73), after adjustment for age,
sex, number of falls, and BUA. In transient transfection
studies, a reporter gene downstream of the –1260(A)-con-
taining promoter was more highly expressed than that con-
taining the C allele. These data suggest that a common but
functional variation within the CYP27B1 promoter gene is
associated with fracture risk in the elderly.
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DOI 10.1007/s00223-010-9434-4Several epidemiologic studies have consistently demon-
strated that fracture tends to cluster within families but the
segregation does not follow a Mendelian pattern [1].
Women whose mother had a hip fracture are at increased
risk of hip fracture compared to those whose mothers did
not sustain a fracture [2]. Approximately 25–35% of the
variance of fracture liability is attributable to genetic factors
[3, 4]. Genetic factors also account for a large proportion of
variance in risk factors of fracture such as bone mineral
density (BMD) [5], bone loss [6], quantitative ultrasound
measurement [7], and bone turnover markers [8].
Speciﬁc genes involved in the regulation of bone mass
and fracture susceptibility have been identiﬁed on the basis
of candidate gene-association studies, such as collagen 1a1
[9] and lipoprotein receptor–related protein 5 (LRP5)[ 10].
More recently, with the advance of genomewide studies, a
number of single-nucleotide polymorphisms (SNPs) have
been associated with fracture and bone density [11–14].
Such studies have shown an association between osteopo-
rosis and SNPs within genes encoding osteoprotegerin,
LRP5, estrogen receptor 1, and receptor activator of
nuclear factor-jB ligand [11–14]. One genomewide study
provided some evidence for an association between vita-
min D receptor (VDR) variants and BMD [11], which was
ﬁrst identiﬁed by Morrison and colleagues [15, 16] but has
been controversial since [17].
One limitation, however, of current genomewide studies
has been incomplete coverage of genetic variation, such
that the replicated SNP associations explain only a small
proportion of the variance in BMD and fracture [18]. This
suggests the existence of other sequence variants that are
associated with osteoporosis, and there is still a role
therefore in studying key candidate genes within physio-
logic pathways known to inﬂuence skeletal health. For
instance, vitamin D is undoubtedly critical for optimal
skeletal mineralization [19], and its active product is gen-
erated by 1a-hydroxylation of 25-hydroxyvitamin D [20].
Coding region mutations in the CYP27B1 gene encoding
1a-hydroxylase cause type I vitamin D–dependent rickets
[21, 22]. Moreover in two large, separate studies a SNP in
the CYP27B1 promoter (rs10877012) was recently associ-
ated with multiple sclerosis [23] and type 1 diabetes [24];
the same allele was responsible for the disease association
in each case and was also associated with other autoim-
mune disorders in smaller studies [25–29]. Since vitamin D
deﬁciency is increasingly common in the elderly and a risk
factor for fracture in postmenopausal women [30], we
hypothesized that CYP27B1 is associated with fracture risk
in the elderly. The present study was therefore designed to
test the hypothesis by examining the association between
CYP27B1 gene polymorphisms and fracture risk in a cohort
of frail elderly subjects, a majority of whom were vitamin
D–insufﬁcient.
Study Design and Methods
Participants
The Fracture Risk Epidemiology in the Frail Elderly
(FREE) Study is an ongoing prospective study of predictors
of falls and fractures in a cohort of men and women living
in residential care facilities in Sydney [31]. Ethical
approval was given by the local institutional Human
Research Ethics Committee. Not all of the 2,005 partici-
pants in the FREE study were able to give consent for
venesection, but all participants who had blood collected at
the baseline are reported here. Of these, 760 of 915 subjects
had DNA available for genotyping.
Measurements
Fracture was ascertained through chart review during reg-
ular visits to institutions (i.e. once every 6–12 weeks) for
2 years from baseline and validated by review of a radi-
ology report. The diagnosis of clinical vertebral fractures
required subjects to have radiologic evidence of vertebral
fracture in association with acute back pain at a corre-
sponding level, but a previous normal X-ray at that verte-
bral level was not required. For the purpose of these
analyses, the following fractures were included: hip, clin-
ical vertebral, pelvis, wrist, humeral, rib, and femoral shaft.
Fractures of the skull, ankle, ﬁnger, and hand were exclu-
ded from the analysis. Falls were ascertained from incident
reports and medical records (examined every 6–12 weeks).
Clinical biochemistry and calcaneal ultrasound mea-
surements have been previously described [31]. Brieﬂy,
morning blood samples were collected at baseline assess-
ment. Serum 25-hydroxyvitamin D was measured by RIA
(DiaSorin, Stillwater, MN). Serum PTH was measured by a
two-site chemiluminescent ELISA on an Immulite 1000
analyzer (Diagnostic Products, Los Angeles, CA). Bone
ultrasound attenuation (BUA) was measured at the calca-
neus in all participants using a MCue CUBA Mark II
ultrasound device [31].
Genotyping
We studied the SNP rs10877012, which lies 1.2 kb
upstream of the transcription start site of CYP27B1
(–1260C[A) and was strongly associated with either type 1
diabetes or multiple sclerosis in two large genotyping
studies [23, 24]. This SNP is predicted to cause a functional
change using the bioinformatics tool F-SNP, which makes
predictions of functionality of variants located within
putative transcription factor binding sites (TFBSs) [32].
Moreover, other SNPs within or up to 10 kb upstream of
the CYP27B1 gene locus (HapMap) are either in near-
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and r
2[0.98), unlikely to be functional by F-SNP
(intronic rs4646537, MAF 0.034; synonymous exon
rs8176345, MAF 0.049), or rare (MAF\0.01). We had
also previously genotyped this cohort for another intra-
genic CYP27B1 SNP rs4646536 (?2838T[C, in intron 6),
which some [24], but not all [25, 27, 28], studies had
suggested was in near-perfect linkage disequilibrium with
rs10877012.
Genomic DNA was extracted from peripheral blood
leucocytes using standard procedures. Genomic DNA was
ampliﬁed by PCR (with an annealing temperature of 60C
in all cases), and genotyping was conducted by restriction
fragment length polymorphism. The CYP27B1 –1260 SNP
was ampliﬁed using primers forward 50-GGC ACA GAG
CCT GAT AGA GTT G-30 and reverse 50-GGC AAC
ATA GTC GAA CTG TCT C-30 and detected with the
HinfI enzyme. The CYP27B1 ?2838 SNP was ampliﬁed
using reverse primer 50-TAG GTT GCA AAG CAC AAA
ATG GAG TCA-30 and a mismatched forward primer
50-GGA AGC AGG GAG ATA GCA GAG -30 that
introduces a HincII restriction site in the presence of the
T allele. PCR products were digested for at least 2 hours at
37C and electrophoresed on agarose gels. All genotypes
were scored by two researchers independently (R. J. C.-B.,
A. A.). Repeat genotyping was conducted in 158 samples
(21% of cohort) with 100% concordance as a quality
control.
Reporter Gene Studies
A reporter construct containing the proximal 1.3 kb of the
human CYP27B1 promoter upstream of the luciferase gene
was a kind gift from Prof. Howard Morris (Hanson Insti-
tute, Adelaide, Australia) [33]. Sequencing of this construct
revealed the C allele at –1260. Standard site-directed
mutagenesis was performed to create another reporter
containing the –1260A CYP27B1 allele (Quik-Change
TM;
Stratagene, La Jolla, CA), and mutagenesis was conﬁrmed
by direct sequencing. Human embryonic kidney HEK293
cells in 24-well plates were transiently transfected using
DMRIE-C (Invitrogen Life Technologies, Carlsbad, CA)
with 10, 50, or 100 ng of either CYP27B1 reporter gene
(–1260A or –1260C) or empty reporter vector (pGL3-basic,
100 ng). A renilla luciferase reporter (Promega, Madison,
WI), 10 ng/well, was used to control for transfection efﬁ-
ciency. Cells were lysed after 48-hour incubation and
then assayed for ﬁreﬂy and renilla luciferase activities
(Promega). The transcriptional response was normalized for
renilla activity, then expressed as a fold change relative to
data from cells transfected with the empty pGL3-basic
reporter. Data represent mean ± SD of three experiments,
each performed in triplicate wells.
Statistical Analysis
The association between the polymorphisms and fracture
was assessed by the Cox proportional hazards model [34],
in which the time to fracture was considered outcome,
whereas age, weight, BUA, and biochemical markers were
covariates. The metric of association was expressed in
terms of hazard ratio (HR) per allele for each polymor-
phism. The hormonal and mineral parameters considered in
the model were serum 25-hydroxyvitamin D, PTH, and
calcium. Because the distribution of these parameters was
skewed, a logarithmic transformation was applied to
‘‘normalize’’ the data and stabilize their variance prior to
the modeling process. In order to estimate the proportion of
fracture liability that may be hypothetically attributable to
the polymorphism, the population-attributable risk fraction
(PARF) was calculated according to the ‘‘sequential
attributable fraction’’ [35]. Analyses were conducted with
the R statistical language (www.r-project.org).
Results
On average, the individuals had been followed for 2.2 years
(range 0.1–5.5). During the follow-up period, 21 men and
116 women had sustained a fragility fracture, with the
incidence of fracture (per 100 person-years) being 6.62 for
men and 9.96 for women. Baseline clinical characteristics
andbiochemical markersstratiﬁed bysexand fracture status
are shown in Table 1. BUA was signiﬁcantly reduced and
fall rate was higher among women with fracture, although
there was no signiﬁcant difference in age and biochemical
markers between the fracture and nonfracture groups.
Of an original cohort of 915 individuals, DNA was
available from 760 subjects for genotyping, of which 11
samples failed to amplify, leaving a total of 749 genotyped
subjects (Table 1). The relative frequency of CYP27B1
–1260 alleles was 0.64C:0.36A, with genotypes AA (14%),
AC (43%), and CC (43%). The CYP27B1 –1260 poly-
morphism was in tight linkage disequilibrium with the
CYP27B1 ?2838 polymorphism (0.65T:0.35C; D0 = 0.96,
r
2 = 0.94 [SE = 0.012]). In each polymorphism the dis-
tribution of genotypes was consistent with Hardy-Wein-
berg equilibrium (P[0.15). There were no signiﬁcant
differences in age, weight, BUA, serum PTH, and creati-
nine among CYP27B1 –1260 genotypes; serum 25(OH)D
was higher in heterozygotes but not signiﬁcantly different
between homozygotes for either –1260 allele (Table 2).
The parameters shown in Table 2 were also analyzed
separately by gender (not shown), and the variation of
25(OH)D by genotype was seen only in men.
The cumulative probability of fracture for each
CYP27B1 –1260 genotype is shown in Fig. 1. Individuals
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the highest incidence of fracture (13.9/100 person-years),
followed by heterozygous individuals (11.6/100 person-
years) and those homozygous for the A allele (7.9/100
person-years). A similar trend was also found for the
CYP27B1 ?2838 polymorphism (Table 3).
Each C allele of the CYP27B1 –1260 polymorphism
was associated with an increased hazard of fracture by
1.28 (95% CI 1.00–1.66, P = 0.05). The association was
unchanged after adjusting for age, sex, number of falls,
and BUA; when analyzed separately, the effect of
CYP27B1 genotype on fracture was not signiﬁcant in men,
although there were far fewer fractures (n = 21) than in
women (n = 116). The ﬁnal predictive model is shown in
Table 4, in which after adjusting for age, number of falls,
and BUA, the HR associated with each C allele was 1.34
(95% CI 1.03–1.73). The number of fracture cases that
can be attributed to the variation at this polymorphism
was 11.4%.
Table 1 Baseline characteristics of participants stratiﬁed by gender
and fracture status
Gender Nonfracture Fracture P
Men (n) 132 21
Age (years) 84.6 (7.5) 86.8 (7.2) 0.201
Weight (kg) 68.4 (11.8) 65.9 (10.9) 0.360
25(OH)D (nmol/l)* 31.0 (21, 44.3) 26.0 (17, 42.3) 0.232
Log (25[OH]D) 3.41 (0.60) 3.16 (0.84) 0.117
PTH (pg/ml)* 49.6 (33, 72.5) 42.0 (29, 67.1) 0.771
Log (PTH) 3.93 (0.66) 3.87 (0.75) 0.772
Creatinine (mmol/l) 101.0 (34.8) 111.3 (16.1) 0.239
Albumin (g/l) 41.1 (3.1) 40.7 (0.5) 0.430
Phosphate (mmol/l) 1.16 (0.18) 1.11 (0.09) 0.242
Corrected Ca (mmol/l) 2.36 (0.15) 2.33 (0.09) 0.390
BUA (dB/MHz) 72.3 (26.5) 63.4 (18.3) 0.071
Fall rate (falls/year)* 0.68 (0, 2.65) 2.52 (1, 6.21) 0.69
Women (n) 480 116
Age (years) 87. (6.4) 87.1 (5.7) 0.838
Weight (kg) 56.2 (12.4) 55.3 (11.6) 0.462
25(OH)D (nmol/l)* 24.0 (17, 36) 27.5 (20, 39.3) 0.040
Log (25[OH]D) 3.18 (0.58) 3.32 (0.55) 0.017
PTH (pg/ml)* 58.0 (39, 90.6) 63.7 (41.2, 95) 0.272
Log (PTH) 4.09 (0.67) 4.08 (0.65) 0.851
Creatinine (mmol/l) 88.2 (32.4) 85.0 (29.8) 0.576
Albumin (g/l) 40.6 (3.2) 39.3 (3.8) 0.082
Phosphate (mmol/l) 1.20 (0.18) 1.22 (0.16) 0.672
Corrected Ca (mmol/l) 2.39 (0.13) 2.40 (0.13) 0.725
BUA (dB/MHz) 46.0 (17.8) 40.7 (14.6) 0.001
Fall rate (falls/year)* 0.59 (0, 2.49) 1.53 (0.84, 3.72) 0.03
Values are mean (SD), except for asterisked variables, for which data
are median (IQR)
Table 2 Baseline characteristics of participants stratiﬁed by CYP27B1 –1260C[A genotype
AA AC CC P
n 108 320 321
Age (years) 86.8 (6.8) 86.5 (6.2) 86.9 (6.9) 0.78
Weight (kg) 59.0 (12.2) 58.1 (13.4) 58.5 (13.0) 0.81
25(OH)D (nmol/l)* 26 (17, 37) 27 (18, 41) 25 (17, 35) 0.02
PTH (pg/ml)* 56.6 (34, 98.7) 55.0 (38, 81.3) 60.0 (39, 90.9) 0.53
Creatinine (mmol/l) 81.4 (17.7) 93.6 (33.1) 90.2 (35.4) 0.16
Albumin (g/l) 39.9 (3.5) 40.8 (3.2) 40.4 (3.2) 0.28
Phosphate (mmol/l) 1.16 (0.22) 1.20 (0.15) 1.21 (0.18) 0.26
Corrected Ca (mmol/l) 2.39 (0.17) 2.39 (0.12) 2.38 (0.12) 0.97
BUA (dB/MHz) 48.1 (17.8) 49.7 (20.8) 51.7 (24.3) 0.28
Fall rate (falls/year)* 0.73 (0, 2.50) 0.82 (0, 2.96) 0.95 (0, 2.82) 0.25
Values are mean (SD), except for asterisked variables, for which data are median (IQR)





































Fig. 1 Cumulative probability of fracture stratiﬁed by CYP27B1
–1260 genotype. Probability of fracture over time (y) is expressed for
each genotype (AA, short dashed line; AC, long dashed line; CC, solid
line)
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We next investigated the functional effect of the CYP27B1
–1260 polymorphism in transfection studies using a 1.3-kb
region of the human CYP27B1 promoter cloned upstream
of the luciferase gene [33]. We determined that the pro-
moter contained the C allele at position –1260 and per-
formed site-directed mutagenesis to generate the A allele at
this position. We conﬁrmed the integrity of the remaining
sequence following mutagenesis by direct sequencing. We
then transfected either reporter in increasing amounts into
human kidney HEK293 cells. We expected that the func-
tional change associated with the –1260C[A SNP would
be subtle (as any SNP associated with a complex pheno-
type) and, therefore, may only be apparent at limiting doses
of the promoter. As shown in Fig. 2, the reporter gene
containing the CYP27B1 –1260A allele was expressed
signiﬁcantly more than that containing the –1260C allele;
at plasmid doses of 10–50 ng/well, the –1260C reporter
was only 70–80% as active as the –1260A-containing
reporter and, as expected, the difference was lost when
higher concentrations (C 100 ng) of each reporter was
used.
Discussion
Vitamin D is important for skeletal health across all ages.
During infancy and childhood, vitamin D deﬁciency leads
to rickets and osteomalacia. In adults, and particularly in
the elderly, vitamin D deﬁciency is a key risk factor for
osteoporotic fractures, and the mechanisms are complex
and may not be solely translated via the known skeletal
effects of vitamin D [36]. The present study represents the
ﬁrst demonstration of an association between SNPs in the
CYP27B1 gene and fracture risk in frail elderly subjects.
The strongest association was with a SNP in the CYP27B1
promoter (–1260C[A); association with a second, intronic
SNP (?2838T[C) could be explained by tight linkage
disequilibrium between the two SNPs, consistent with the
study by Bailey et al. [24]. Our functional data that the
–1260C allele leads to lower gene expression is consistent
Table 3 Frequency distribution
of genotypes in fracture and
nonfracture groups





AA 95 13 12.0 7.9
AC 263 57 17.8 11.6
CC 254 67 20.9 13.9
CYP27B1 ?2838T[C
CC 87 13 13.0 8.4
TC 265 55 17.2 11.2
TT 247 66 21.1 14.1
Table 4 Independent predictors of fracture risk
Risk factors Hazard ratio 95% CI P
CYP27B1 –1260 allele
a 1.34 1.03–1.73 0.027
Age (per 5 years) 1.05 0.91–1.20 0.528
Falls 1.02 1.00–1.05 0.034
BUA (–20) 1.45 1.21–1.75 \0.001
CYP27B1 ?2838 allele
a 1.33 1.03–1.72 0.027
Age (per 5 years) 1.03 0.90–1.18 0.671
Falls 1.03 1.00–1.05 0.023
BUA (–20) 1.46 1.21–1.76 \0.001
a The magnitude of association is expressed per C allele (–1260) or
T allele (?2838). For age and BUA, the hazard ratio was computed




























Fig. 2 CYP27B1 promoter activity in vitro. HEK293 cells were
transfected with a luciferase reporter gene with the 1.3-kb CYP27B1
promoter containing either the –1260C or the –1260A allele.
Luciferase expression in each case was normalized for an internal
transfection control (renilla) and expressed relative to activity from
cells transfected with the empty reporter plasmid (pGL3-basic). Data
are mean ± SD of three experiments, each performed in triplicate
wells. CYP27B1 –1260C allele, white bars; CYP27B1 –1260A allele,
solid bars. Signiﬁcance was determined by Student’s t-test
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123with another recent study that found lower CYP27B1
mRNA expression in peripheral blood mononuclear cells
from type 1 diabetic patients homozygous for the –1260C
allele [26]. Moreover, the –1260C allele changes a con-
sensus CDX2 transcription factor binding site within the
CYP27B1 promoter [29], and a CDX2-binding site poly-
morphism within the VDR promoter [37, 38] has recently
been signiﬁcantly associated with vertebral fracture in a
large multicenter study [39]. The functional consequence
of the CYP27B1 –1260C allele (Fig. 2) is similar in mag-
nitude to that reported for the VDR CDX2 polymorphism
in vitro [37]. Taken together, we propose that the CYP27B1
–1260C SNP is associated with skeletal fragility via
reduced expression of 1a-hydroxylase, in particular since
the majority of our subjects were vitamin D–insufﬁcient.
Further arguments in favor of a functional effect of this
SNP include reports that the same CYP27B1 –1260C allele
is associated with type 1 diabetes [24–26] and other endo-
crine autoimmune disorders [27–29]. In the largest study,
CYP27B1 –1260C was associated with an increased risk of
type 1 diabetes in 7,854 cases compared with 8,758 controls
(OR = 1.07), and in 2,774 affected families (RR = 1.11),
with the combined association at P = 3.8 9 10
-6 [24].
There is strong evidence that vitamin D deﬁciency is
associated with type 1 diabetes [40]. The association of the
CYP27B1 –1260C variant with diabetes has been proposed
to be due to lower systemic availability of calcitriol or
alternatively to reduced CYP27B1 expression in immune
regulatory cells [41].
The association between the CYP27B1 –1260C allele
and fracture in our study might also therefore be mediated
via reduced CYP27B1 expression within the kidney leading
to reduced circulating calcitriol concentrations. Arguing
against this possibility, however, is that serum PTH con-
centrations were not signiﬁcantly higher in subjects with
the –1260C SNP as might have been expected by virtue of
the strong negative feedback relationship between calcitriol
and PTH. Other factors, such as age and renal impairment,
may have obscured this association in our cohort, but
multivariable regression models did not support this con-
clusion (data not shown).
Three alternate hypotheses might explain the association
between CYP27B1 polymorphisms and fracture. Firstly,
CYP27B1 is expressed in osteoblasts and has been pro-
posed to mediate osteoblast differentiation [42]. Alteration
of this osteoblast CYP27B1 expression might therefore
affect skeletal integrity without measurable alteration in
circulating calcitriol levels. However, we did not ﬁnd an
association between the –1260 SNP and BUA. Secondly,
there is evidence that vitamin D deﬁciency is associated
with the risk of falling [36]. However, we did not ﬁnd an
association between the –1260C CYP27B1 allele and fall
risk in our cohort. A third possibility is suggested by the
fact that CYP27B1 is expressed in the intestine [43], where
CDX2 is primarily expressed and known to regulate VDR
expression [44]. Since the –1260C allele changes a CDX2
binding site within the CYP27B1 promoter, it is conceiv-
able that altered intestinal CYP27B1 expression might
affect intestinal calcium absorption, possibly in combina-
tion with the VDR promoter CDX2 polymorphism. These
hypotheses require further study.
The present ﬁndings should be interpreted within the
context of strengths and potential weaknesses. This cohort
represents an ideal group for the study of genetic associa-
tions with fracture since the incidence of fractures in our
sample is high, making it possible to identify associations
with a smaller number of participants. We note that our
study adds to the few genetic markers associated with
fracture including the COLIA1 Sp1 polymorphism [45] and
LRP5 polymorphisms [12]. Nevertheless, this is a relatively
small sample size, and we would certainly argue that our
ﬁndings must be replicated in other, larger cohorts.
Moreover, the CYP27B1 variant did not affect BUA;
therefore, this gene may only be important for fractures in
the vitamin D–insufﬁcient frail elderly, and further studies
are required to determine its importance in osteoporosis in
general.
In conclusion, these data suggest that the 1a-hydroxy-
lase gene CYP27B1 is an important novel candidate con-
tributor to osteoporosis. Given the facts that this enzyme is
a critical regulator of vitamin D biosynthesis and that
mutations within the coding region of CYP27B1 cause
vitamin D–dependent rickets type I [21, 22], the present
ﬁndings have a strong biologic basis. Since the 1a-
hydroxylase gene also represents a therapeutic target, the
ﬁnding reinforces the concept that this is a candidate for
further study, in particular to establish whether the poly-
morphism might predict clinical response to vitamin D
therapy [36, 46].
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